Valbiotis S.A.
ALVAL.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.35 | 0.16 | -0.10 | -0.08 |
| FCF Yield | -49.14% | -13.33% | -26.03% | -12.08% |
| EV / EBITDA | -1.98 | -6.89 | -2.04 | -5.31 |
| Quality | ||||
| ROIC | -64.40% | -21.08% | -59.00% | -41.12% |
| Gross Margin | -1,396.00% | 56.81% | 97.71% | 94.63% |
| Cash Conversion Ratio | 1.15 | 1.09 | 0.75 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | -39.37% | 151.37% | -36.68% | 48.50% |
| Free Cash Flow Growth | -42.09% | 12.42% | -25.12% | -420.79% |
| Safety | ||||
| Net Debt / EBITDA | 0.64 | 2.83 | 1.23 | 1.56 |
| Interest Coverage | -45.32 | -32.40 | -48.97 | -31.24 |
| Efficiency | ||||
| Inventory Turnover | 1.25 | 2.03 | 0.03 | 0.04 |
| Cash Conversion Cycle | 5,305.30 | 172.75 | -19,817.02 | -20,331.30 |